<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475783</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0127</org_study_id>
    <secondary_id>DRKS00022452</secondary_id>
    <nct_id>NCT04475783</nct_id>
  </id_info>
  <brief_title>Sirolimus- vs. Paclitaxel-Drug Coated Ballons in Patients With Peripheral Artery Disease</brief_title>
  <acronym>SIRONA</acronym>
  <official_title>Head-to-Head Comparison of SIROlimus Versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Concept Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vascuscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CoreLab Black Forest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Clinical Studies Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, interventional, multi-center 1:1 randomized non-inferiority&#xD;
      trial.&#xD;
&#xD;
      The trial evaluates the safety and efficacy of the Magic Touch PTA sirolimus drug-coated&#xD;
      balloon in comparison to the treatment with PTX drug-coated balloon (control device) in&#xD;
      patients with femoropopliteal artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in&#xD;
      the obstructed artery for several seconds to minutes, has become the standard endovascular&#xD;
      treatment for peripheral arteries. The long-term success of bare balloon PTA in the&#xD;
      fem-oropopliteal segment is hampered by the occurrence of restenosis, which can be reduced by&#xD;
      local antiproliferative drug delivery via the PTA balloon catheter.&#xD;
&#xD;
      The rationale of this study is based on the hypothesis that the usage of the Sirolimus-coated&#xD;
      Magic Touch Sirolimus DCB is at least equal (non-inferior) with regards to efficacy and&#xD;
      safety in comparison with a clinically well-established PTX coated balloon.&#xD;
&#xD;
      The objective of this prospective, randomized, multi-center, post-market study is to compare&#xD;
      the Magic Touch Sirolimus DCB with Paclitaxel-coated DCB for treatment of high grade&#xD;
      ste-notic or occluded lesions in SFA and / or P1 segment of the popliteal artery (PA) in PAD&#xD;
      pa-tients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1-randomization, parallel design, stratified by Center.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency rate (Absence of clinically driven target lesion revascularization)</measure>
    <time_frame>one year after study procedure (PTA with medical product under investigation or comparator)</time_frame>
    <description>patency rate after one year defined as absence of clinically driven target lesion revascularization (TLR) due to symptoms and drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-procedure or restenosis with PVR &gt; 2.4 evaluated by duplex ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety outcome</measure>
    <time_frame>through 12 months post-procedure</time_frame>
    <description>Composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target vessel vessel revasculariza-tion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLR rate</measure>
    <time_frame>1, 6, 12, 24, 36, 48 and 60 months after study procedure</time_frame>
    <description>ocurrence of Target lesion revascularization (TLR) at certain time Points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>at 12 months after study procedure</time_frame>
    <description>Sustained clinical improvement: an improvement shift in the Rutherford classification of one class in amputation and TVR free surviving patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity assessment 1</measure>
    <time_frame>at 1, 6, 12, 24, 36, 48 and 60 months after study procedure</time_frame>
    <description>patient-self-assessment of walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity assessment 2</measure>
    <time_frame>at 6, 12, 24, 48 months after study procedure</time_frame>
    <description>6-minute Walking test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity assessment 3</measure>
    <time_frame>at 6, 12, 24, 48 months after study procedure</time_frame>
    <description>Treadmill test (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity assessment 4</measure>
    <time_frame>at 6, 12, 24, 48 months after study procedure</time_frame>
    <description>Walking Impairment Questionnaire (WIQ); 20 questions (scale 0 to 4); best score 0, worst score 80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duplex Ultrasound</measure>
    <time_frame>post-procedure and at 6, 12, 24 and 48 months or at any time of re-intervention</time_frame>
    <description>Duplex-defined binary restenosis (PSVR &gt;2.4) of the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI</measure>
    <time_frame>at discharge, 6, 12, 24 and 48 months</time_frame>
    <description>Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualilty of Life Assessment</measure>
    <time_frame>at 1 month, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Quality of life assessment (QoL) by EQ5D-3L questionnaire; 5 questions (scale 1 to 5), best score 5, worst score 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety: freedom from all cause death, target limb major amputation and clinically-driven target vessel revascularization</measure>
    <time_frame>trough 60 months after study procedure</time_frame>
    <description>Composite of freedom from all cause death through 60 months post procedure as well as freedom from both target limb major amputation and clinically-driven target vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">478</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sirolomus DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with Sirolimus-coated balloon catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel DCB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with Paclitaxel-coated balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty (PTA)</intervention_name>
    <description>PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery</description>
    <arm_group_label>Paclitaxel DCB group</arm_group_label>
    <arm_group_label>Sirolomus DCB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject age ≥ 18&#xD;
&#xD;
          2. Subject has been informed on the nature of the study, the duration of the study,&#xD;
             agrees to attend follow-up visits, agrees to complete the required testing, agrees to&#xD;
             participate, and has signed an informed consent form.&#xD;
&#xD;
          3. Rutherford category 2-4 according to the investigator's subjective evaluation&#xD;
&#xD;
          4. Subject has a de novo or re-stenosed lesion with ≥ 70 % stenosis documented&#xD;
             angiographically&#xD;
&#xD;
          5. Target lesion length is ≥ 2 cm and ≤ 20 cm by visual estimate of the treating&#xD;
             physician&#xD;
&#xD;
          6. Multiple lesions with max. 3 cm healthy vessel segment in between lesions can be&#xD;
             considered at the discretion of the operator as one lesion. Total lesion length should&#xD;
             not exceed 20 cm&#xD;
&#xD;
          7. Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual estimation&#xD;
&#xD;
          8. Patency of P2 and P3 segment of the popliteal artery and at least one (1)&#xD;
             infrapopliteal artery to the ankle (&lt; 50 % diameter stenosis) in continuity with the&#xD;
             femoropopliteal artery&#xD;
&#xD;
          9. Patency of ipsilateral iliac artery (≤ 30% diameter stenosis). Iliac artery stenosis &gt;&#xD;
             30 % may be treated during the index procedure to ensure sufficient inflow.&#xD;
&#xD;
         10. A guidewire has successfully traversed the target treatment segment intraluminal&#xD;
&#xD;
         11. Vascular disease in the opposite leg that requires treatment at the time point of&#xD;
             index procedure is allowed, but has to be treated according to randomization or with&#xD;
             POBA.&#xD;
&#xD;
         12. A patient can only be enrolled and randomized once with only one target lesion in the&#xD;
             SIRONA trial. Please note that only the lesion in one limb can be treated as target&#xD;
             lesion for index procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to successfully cross the target lesion or subintimal target lesion guidewire&#xD;
             crossing&#xD;
&#xD;
          2. Flow-limiting dissection after pre-dilatation&#xD;
&#xD;
          3. Angiographic evidence of severe calcification of the target vessel (contiguous&#xD;
             calcification on both sides of the vessel)&#xD;
&#xD;
          4. Presence of fresh thrombus in the target lesion&#xD;
&#xD;
          5. Presence of aneurysm in the target vessel/s&#xD;
&#xD;
          6. Prior vascular surgery (including atherectomy, bypass surgery) of the target limb&#xD;
&#xD;
          7. Prior stent in the target lesion&#xD;
&#xD;
          8. Stroke or heart attack within 3 months prior to enrollment&#xD;
&#xD;
          9. Any vascular surgical procedure or intervention performed in the target limb within 30&#xD;
             days prior to or planned within 30 days post index procedure&#xD;
&#xD;
         10. Any vascular treatment with PTX or sirolimus-coated devices 60 days prior to index&#xD;
             procedure&#xD;
&#xD;
         11. Target lesion requires treatment with alternative therapies such as primary stenting,&#xD;
             laser, lithotripsy, thrombectomy, atherectomy, cryoplasty, brachytherapy, re-entry&#xD;
             devices&#xD;
&#xD;
         12. Enrolled in another investigational drug, device or biologic study&#xD;
&#xD;
         13. Life expectancy of less than one year in the investigator's opinion&#xD;
&#xD;
         14. Known allergies or sensitivity to heparin, aspirin, other anticoagulant/ antiplatelet&#xD;
             therapies, sirolimus, paclitaxel or contrast media that cannot be adequately&#xD;
             pre-treated prior to index procedure&#xD;
&#xD;
         15. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate&#xD;
             the use of anti-platelet therapy&#xD;
&#xD;
         16. Receiving dialysis or immunosuppressant therapy&#xD;
&#xD;
         17. Pregnant or lactating females&#xD;
&#xD;
         18. History of major amputation in the same limb as the target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Teichgraeber, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Jena, Institute of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulf Teichgraeber, Prof. Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9 324806</phone_ext>
    <email>ulf.teichgraeber@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Graziani, M.A.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9 324910</phone_ext>
    <email>laura.graziani@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz, Klinische Abteilung für Angiologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Brodmann, Prof</last_name>
      <phone>+43 316 385 12911</phone>
      <phone_ext>12911</phone_ext>
      <email>marianne.brodmann@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee, Institut für Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus A Hausegger</last_name>
      <phone>+43 463 538 38503</phone>
      <phone_ext>38503</phone_ext>
      <email>Klaus.Hausegger@kabeg.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Universitätsklinik für Innere Medizin II, Klinische Abteilung für Angiologie</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Schlager, Prof.</last_name>
      <phone>+43 (0)1 40400</phone>
      <phone_ext>46710</phone_ext>
      <email>oliver.schlager@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Radiologie und Nuklearmedizin, Klinische Abteilung für Kardiovaskuläre und Interventionelle Radiologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Wolf, Prof</last_name>
      <phone>+43 1 40 400 58020</phone>
      <phone_ext>58020</phone_ext>
      <email>florian.wolf@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Werner, PD Dr.</last_name>
      <phone>+43 1 91021</phone>
      <phone_ext>-57812</phone_ext>
      <email>martin.werner@wgkk.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg, Klinik für Diagnostische und Interventionelle Radiologie und Neuroradiologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kröncke, Prof</last_name>
      <phone>+49 821 400 2441</phone>
      <phone_ext>2441</phone_ext>
      <email>thomas.kroencke@klinikum-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, Prof. Dr.</last_name>
      <phone>+49 7633</phone>
      <phone_ext>402 - 4973</phone_ext>
      <email>Thomas.Zeller@universitaets-herzzentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin, Klinik für Radiologie</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maximilian De Bucourt, PD Dr</last_name>
      <phone>+49 30 450 527 855</phone>
      <phone_ext>855</phone_ext>
      <email>maximilian.de-bucourt@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fürst-Stirum-Klinik Bruchsal, Klinik für Kardiologie, Angiologie, Diabetologie, Neurologie und Intensivmedizin</name>
      <address>
        <city>Bruchsal</city>
        <zip>76646</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Andrassy, Prof.</last_name>
      <phone>+49 7251 708 57791</phone>
      <phone_ext>57791</phone_ext>
      <email>martin.andrassy@rkh-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden, Institut und Poliklinik für Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf-Thorsten Hoffmann, Prof</last_name>
      <phone>+49 351 458 2259</phone>
      <phone_ext>2259</phone_ext>
      <email>ralf-thorsten.hoffmann@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Westdeutsches Herz- und Gefäßzentrum Essen, Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Rammos, Prof.</last_name>
      <phone>+49 201 723 84808</phone>
      <phone_ext>84808</phone_ext>
      <email>Christos.Rammos@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DIAKO Krankenhaus gGmbH, Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Müller-Hülsbeck, Prof</last_name>
      <phone>+49 461 812 1800</phone>
      <phone_ext>1800</phone_ext>
      <email>muehue@diako.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Radiologie</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Wohlgemuth, Prof.</last_name>
      <phone>+49 345 557-2742</phone>
      <phone_ext>-2742</phone_ext>
      <email>Walter.Wohlgemuth@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik III, Kardiologie, Angiologie und Pneumologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Erbel, Prof.</last_name>
      <phone>+49 6221 56 8612</phone>
      <phone_ext>8612</phone_ext>
      <email>christian.erbel@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Allgäu gGmbH, Herz- und Gefäßzentrum Oberallgäu Kempten, Klinik Immenstadt</name>
      <address>
        <city>Immenstadt Im Allgäu</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wulf Ito, Prof</last_name>
      <phone>+49 8323 910 8701</phone>
      <phone_ext>8701</phone_ext>
      <email>wulf.ito@klinikverbund-allgaeu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Teichgraeber, Prof. Dr.</last_name>
      <phone>+49 3641 9</phone>
      <phone_ext>32 4806</phone_ext>
      <email>ulf.teichgraeber@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld, Institut für Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Freyhardt, Dr</last_name>
      <phone>+49 2151 32 100 32</phone>
      <phone_ext>100 32</phone_ext>
      <email>patrick.freyhardt@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Angiologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dierk Scheinert, Prof.</last_name>
      <phone>+49 341 97 18770</phone>
      <phone_ext>18770</phone_ext>
      <email>Dierk.Scheinert@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz, Klinik für Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörn-Oliver Balzer, Prof.</last_name>
      <phone>06131 575831700</phone>
      <phone_ext>1700</phone_ext>
      <email>joern.balzer@marienhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gefäßpraxis im Tal</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Heilmeier, Dr</last_name>
      <phone>+49 89-2421586</phone>
      <phone_ext>1586</phone_ext>
      <email>BrittaH@angiopraxis.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital GmbH, Klinik für Gefäßchirurgie</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bosiers, Dr.</last_name>
      <phone>+49 251 935</phone>
      <phone_ext>5829</phone_ext>
      <email>Michel.Bosiers@sfh-muenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Kardiologie I, Koronare Herzkrankheit, Herzinsuffizienz und Angiologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Malyar, Prof.</last_name>
      <phone>+49 251-83-47688</phone>
      <phone_ext>-47688</phone_ext>
      <email>Nasser.Malyar@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Radebeul, Gefäßzentrum</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Fuss, Dr</last_name>
      <phone>+49 351 833 4542</phone>
      <phone_ext>4542</phone_ext>
      <email>torsten.fuss@elblandkliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imland Klinik Rendsburg, Institut für Diagnostische und Interventionelle Radiologie/Neuroradiologie</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Wissgott, Dr</last_name>
      <phone>+49 4331 200 6001</phone>
      <phone_ext>6001</phone_ext>
      <email>christian.wissgott@imland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Riesa, Gefäßzentrum</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Fuss, Dr</last_name>
      <phone>+49 351 833 4542</phone>
      <phone_ext>4542</phone_ext>
      <email>torsten.fuss@elblandkliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim, Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Tepe, Prof.</last_name>
      <phone>+49 8031 3653551</phone>
      <phone_ext>53551</phone_ext>
      <email>gunnar.tepe@ro-med.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MEDINOS-Kliniken Sonneberg, Gefäßzentrum</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Thieme, MD</last_name>
      <phone>+49 3675 821 2012</phone>
      <phone_ext>2012</phone_ext>
      <email>marcus.thieme@regiomed-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Torgau, Abt. Innere Medizin / Angiologie</name>
      <address>
        <city>Torgau</city>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Maiwald</last_name>
      <phone>+49 3421 77 22 41</phone>
      <phone_ext>22 41</phone_ext>
      <email>maiwald@kkh-torgau.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Ulf Teichgräber</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Drug-Coated Balloon</keyword>
  <keyword>Percuteanous Transaluminal Angioplasty</keyword>
  <keyword>PPA</keyword>
  <keyword>SFA</keyword>
  <keyword>MagicTouch PTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

